[go: up one dir, main page]

WO2006055178A3 - Anti-addl antibodies and uses thereof - Google Patents

Anti-addl antibodies and uses thereof Download PDF

Info

Publication number
WO2006055178A3
WO2006055178A3 PCT/US2005/038125 US2005038125W WO2006055178A3 WO 2006055178 A3 WO2006055178 A3 WO 2006055178A3 US 2005038125 W US2005038125 W US 2005038125W WO 2006055178 A3 WO2006055178 A3 WO 2006055178A3
Authority
WO
WIPO (PCT)
Prior art keywords
addls
antibodies
disease
useful
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/038125
Other languages
French (fr)
Other versions
WO2006055178A2 (en
Inventor
Paul Acton
Zhiqiang An
Andrew J Bett
Robert Breese
Elizabeth Chen Dodson
Gene Kinney
William Klein
Mary P Lambert
Xiaoping Liang
Paul Shughrue
William R Strohl
Kirsten L Viola
Lei Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Merck and Co Inc
Original Assignee
Northwestern University
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2007538122A priority Critical patent/JP5173426B2/en
Priority to AU2005306997A priority patent/AU2005306997B2/en
Priority to US11/577,426 priority patent/US7811563B2/en
Priority to EP05820737.4A priority patent/EP1812062B1/en
Priority to CA2584859A priority patent/CA2584859C/en
Priority to NZ554725A priority patent/NZ554725A/en
Priority to BRPI0516962-3A priority patent/BRPI0516962A/en
Application filed by Northwestern University, Merck and Co Inc filed Critical Northwestern University
Publication of WO2006055178A2 publication Critical patent/WO2006055178A2/en
Priority to BRPI0617480A priority patent/BRPI0617480A2/en
Priority to IL182554A priority patent/IL182554A0/en
Anticipated expiration legal-status Critical
Publication of WO2006055178A3 publication Critical patent/WO2006055178A3/en
Priority to NO20072700A priority patent/NO20072700L/en
Priority to IL190502A priority patent/IL190502A0/en
Priority to US12/901,738 priority patent/US8889138B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer’s Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer’s Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
PCT/US2005/038125 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof Ceased WO2006055178A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2007538122A JP5173426B2 (en) 2004-10-25 2005-10-21 Anti-ADDL antibodies and uses thereof
AU2005306997A AU2005306997B2 (en) 2004-10-25 2005-10-21 Anti-ADDL antibodies and uses thereof
US11/577,426 US7811563B2 (en) 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof
EP05820737.4A EP1812062B1 (en) 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof
CA2584859A CA2584859C (en) 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof
NZ554725A NZ554725A (en) 2004-10-25 2005-10-21 Anti-ADDL antibodies and uses thereof
BRPI0516962-3A BRPI0516962A (en) 2004-10-25 2005-10-21 isolated antibody, or fragment thereof, pharmaceutical composition, methods for preventing the binding of diffusible abeta-derived ligands to a neuron, to inhibit the formation of diffusible ligands, to block protein phosphorylation, to treat a disease prophylactically or therapeutically, to identify a therapeutic agent, detect diffusible ligands, and diagnose a disease, and, kit to detect diffusible ligands
BRPI0617480A BRPI0617480A2 (en) 2004-10-25 2006-10-17 ISOLATED ANTIBODY OR FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION, METHODS FOR PREVENTING BINDING OF DIFUSIBLE AB-DERIVATIVE LIGANDS INTO A NEURON, FOR INHIBITING THE ASSEMBLY OF DIFFUSIBLE AB-DERIVATIVE LIGANDS, FOR BLOCKING THE PHOSPHORYLATION OF A TAU PROTEIN IN SER202/THR205, TO IDENTIFY A THERAPEUTIC AGENT WHICH PREVENTS THE BINDING OF DIFUSIBLE AB-DERIVATIVE LIGANDS INTO A NEURON, TO DETECT DIFFUSIBLE Ab-DERIVATIVE LIGANDS, AND TO DIAGNOSE A DISEASE ASSOCIATED WITH DIFFUSIBLE AB-DERIVATIVE LIGANDS, USE OF A PHARMACEUTICAL COMPOSITION, AND, KIT FOR DETERCING DIFFUSIBLE LIGANDS FROM AB DERIVATIVES
IL182554A IL182554A0 (en) 2004-10-25 2007-04-15 Anti-addl antibodies and uses thereof
NO20072700A NO20072700L (en) 2004-10-25 2007-05-25 Anti-ADDL antibodies and uses thereof
IL190502A IL190502A0 (en) 2004-10-25 2008-03-27 Anti-addl monoclonal antibody and use thereof
US12/901,738 US8889138B2 (en) 2004-10-25 2010-10-11 Anti-ADDL antibodies and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62177604P 2004-10-25 2004-10-25
US60/621,776 2004-10-25
US65253805P 2005-02-14 2005-02-14
US60/652,538 2005-02-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/577,426 A-371-Of-International US7811563B2 (en) 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof
US12/901,738 Division US8889138B2 (en) 2004-10-25 2010-10-11 Anti-ADDL antibodies and uses thereof

Publications (2)

Publication Number Publication Date
WO2006055178A2 WO2006055178A2 (en) 2006-05-26
WO2006055178A3 true WO2006055178A3 (en) 2007-05-03

Family

ID=36407593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/038125 Ceased WO2006055178A2 (en) 2004-10-25 2005-10-21 Anti-addl antibodies and uses thereof

Country Status (12)

Country Link
US (5) US7811563B2 (en)
EP (2) EP1812062B1 (en)
JP (4) JP5173426B2 (en)
KR (1) KR20070094890A (en)
AU (1) AU2005306997B2 (en)
BR (2) BRPI0516962A (en)
CA (1) CA2584859C (en)
IL (2) IL182554A0 (en)
NO (1) NO20072700L (en)
NZ (1) NZ554725A (en)
RU (1) RU2007119382A (en)
WO (1) WO2006055178A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5362164B2 (en) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー Prevention and treatment of Alzheimer's disease
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP5137053B2 (en) 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Anti-factor B antibody or antigen-binding fragment thereof, composition containing the same, antigen-binding polypeptide, and therapeutic agent
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1812062B1 (en) * 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
ES2881353T3 (en) 2004-11-16 2021-11-29 Humanigen Inc Exchange of immunoglobulin variable region cassettes
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
JP5707024B2 (en) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Agents that inhibit the complement alternative pathway to treat traumatic brain injury, spinal cord injury and related conditions
CA2620936A1 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
JP5289963B2 (en) * 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション Anti-ADDL monoclonal antibody and use thereof
WO2007062088A1 (en) * 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
UA102368C2 (en) * 2005-12-12 2013-07-10 Ас Иммуне С.А. SPECIFIC IN RELATION b-AMYLOID 1-42 MONOKLONAL'NI ANTIBODIES WHICH ARE THERAPEUTIC CHARACTERISTICS
MX358175B (en) 2005-12-12 2018-08-08 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties.
EP1996227A2 (en) * 2006-02-24 2008-12-03 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
US8025878B2 (en) 2006-03-23 2011-09-27 Bioarctic Neuroscience Ab Protofibril selective antibodies and the use thereof
ES2436112T3 (en) * 2006-07-14 2013-12-27 Ac Immune S.A. Humanized antibody
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
EP3988566A1 (en) * 2006-07-14 2022-04-27 AC Immune SA Humanized antibody against amyloid beta
BRPI0719763A2 (en) * 2006-10-02 2014-01-28 Ac Immune Sa ANTIBODY, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, CELL, COMPOSITION, MIXTURE, USE OF A CHEMICAL ANTIBODY OR A FRAGMENT OF THE SAME OR A FRAGMENT OF THE SAME AND / OR A PART OR A FUNCTION OR A PART OR A FUNCTION MIXTURE, METHODS FOR PREPARING A PHARMACEUTICAL COMPOSITION OR MIXTURE, TO PREVENT, TREAT OR RELIEVE THE EFFECTS OF A DISEASE, DIAGNOSTIC DISEASE, OR CONDITION ASSOCIATED WITH A DETERMINATION OF THE DETERMINATION OF CAROGUE DETERMINATION IN A FABRIC AND / OR BODY FLUIDS, TEST KITS FOR DISEASE AND DIAGNOSTIC TESTING AND CONDITIONS ASSOCIATED WITH AMYLOID, LIGHT CHAIN VARIABLE REGION, HEAVY CIRCLE, GENELE DESENGER, GENELE DIAGET LINES PRE-FORMED BETA-AMYLOID FIBERS TO PREVENT ABETA-INDUCED NEURON DEGRADATION, TO DIAGNOSE A PREDISPOSITION TO A DISEASE OR CO NDITION ASSOCIATED WITH AMYLOID IN A PATIENT, TO MONITOR MINIMUM RESIDUAL DISEASE IN A PATIENT, TO PROGNOSE LIABILITY OF A PATIENT WHO IS TREATED WITH AN ANTIBODY OR A COMPOSITION OF VACCINE, TO REDUCE THE CARBON LOAD TO THE CIRCLE THE NUMBER OF PLATES IN AN ANIMAL BRAIN, TO REDUCE THE TOTAL SOLUBLE OPEN QUANTITY IN AN ANIMAL BRAIN AND TO HOLD OR INCREASE COGNITIVE MEMORY CAPACITY IN A MAMMALIAN.
JP5238710B2 (en) * 2006-10-19 2013-07-17 シーエスエル、リミテッド High affinity antibody antagonist of interleukin-13 receptor alpha 1
WO2008060814A2 (en) * 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
JP2010507366A (en) * 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド Antibody antagonist of interleukin-13 receptor α1
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
BRPI0808227A2 (en) * 2007-03-14 2014-07-08 Taligen Therapeutics Inc HUMANIZED ANTI-FACTOR B ANTIBODY
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CA2689120C (en) * 2007-06-04 2017-07-11 Vib Vzw Targeted induction of aggregation of proteins with cross beta structures
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2009445A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
KR20100115340A (en) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Antibodies that specifically bind to Aβ oligomers and use thereof
DK3002298T3 (en) 2007-11-21 2019-10-28 Univ Oregon Health & Science ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
AU2009211635B2 (en) * 2008-02-08 2014-06-26 National Center For Geriatrics And Gerontology Antibody capable of binding specifically to Abeta-oligomer, and use thereof
AT506819B1 (en) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh VACCINE FOR THE TREATMENT OF ALZHEIMER DISEASE
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US20110144311A1 (en) * 2008-08-14 2011-06-16 Rebecca Chmielowski Methods for purifying antibodies using protein a affinity chromatography
US9090679B2 (en) 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP2463369A4 (en) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Humanized anti-amyloid-b oligomer antibody
AU2010279892B8 (en) * 2009-08-07 2014-09-25 Oncotherapy Science, Inc. Humanized anti-amyloid-b oligomer antibody
CN102574924A (en) 2009-09-03 2012-07-11 先灵公司 Anti-gitr antibodies
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
US8694430B2 (en) * 2009-11-24 2014-04-08 Rakuten, Inc. Information processing device, information processing method, program and storage medium
RS55738B1 (en) * 2010-02-24 2017-07-31 Immunogen Inc IMMUNOCONCLUSIVE AGAINST FOLATIC RECEPTOR 1 AND THEIR USES
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (en) 2010-03-10 2014-07-31 Probiodrug Ag Heterocyclic glutaminyl cyclase inhibitors (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US20130115227A1 (en) 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
EP2613799A1 (en) 2010-09-07 2013-07-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
AU2011310664B2 (en) 2010-09-27 2016-02-18 Zestagen, S.A. Compositions and methods for treating neoplasia
EP2625198B1 (en) * 2010-10-07 2015-07-22 AC Immune S.A. Antibodies recognising phospho-tau
CN103874707B (en) * 2010-11-19 2017-04-19 卫材R&D管理有限公司 Neutralizing anti-CCL 20 antibodies
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
BR112013025415B1 (en) 2011-04-01 2021-03-16 Immunogen, Inc use of a folate antireceptor immunoconjugate 1 (folr1)
DK2732289T3 (en) 2011-07-13 2018-05-22 Acumen Pharmaceuticals Inc ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SI2760471T1 (en) 2011-09-30 2017-04-26 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2013054110A2 (en) * 2011-10-10 2013-04-18 University Of Lancaster Compositions for binding to amyloid proteins
JP6431372B2 (en) * 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド Antibody formulations and methods
DE102011057019A1 (en) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard for the quantification of pathogenic aggregates from endogenous proteins
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
EP2846819B1 (en) 2012-05-09 2017-05-03 Yeda Research and Development Co. Ltd. Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
MX362514B (en) 2012-08-31 2019-01-22 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1.
KR20150130462A (en) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. Therapeutic peptides
PL3038650T3 (en) 2013-08-30 2021-11-22 Immunogen, Inc. ANTIBODIES AND TESTS FOR THE DETECTION OF THE FOIL RECEPTOR 1
RS60031B1 (en) 2013-12-20 2020-04-30 Hoffmann La Roche Humanized anti-tau(ps422) antibodies and methods of use
CA2939006A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
CN112390881B (en) 2014-07-10 2025-02-21 生命北极神经科学公司 Improved Aβ protofibril binding antibodies
EP3273994B1 (en) 2015-03-27 2021-12-01 University of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
EP3274369A4 (en) * 2015-03-27 2018-10-17 University of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
PL3313877T3 (en) 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
KR102700777B1 (en) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 Combination of therapeutic agents comprising anti-FOLR1 immunoconjugates
JP2017132742A (en) * 2016-01-29 2017-08-03 国立大学法人 大分大学 NOVEL PHARMACOLOGICAL APPLICATION OF Aβ OLIGOMER SPECIFIC ANTIBODY
EP3436476A4 (en) * 2016-03-28 2020-04-29 The Regents of The University of California ANTI-RYK ANTIBODIES AND METHODS OF USE THEREOF
AU2017354743A1 (en) 2016-11-07 2019-06-06 DegenRx B.V Novel amyloid beta oligomer specific binding molecule
US20190336598A1 (en) 2016-12-29 2019-11-07 University Of Miami Methods for modulating inflammasome activity and inflammation in the lung
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3574020B1 (en) * 2017-07-18 2024-05-15 The University of British Columbia Antibodies to amyloid beta
CN111201030B (en) 2017-07-25 2024-11-01 真和制药有限公司 Treating cancer by blocking the interaction between TIM-3 and its ligands
CN111050797B (en) * 2017-07-28 2024-04-30 凡恩世制药(北京)有限公司 Anti-TIM-3 antibodies and uses thereof
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2019155459A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Inhibitors of the 20s proteasome
KR20210071944A (en) * 2018-07-03 2021-06-16 더 유니버시티 오브 마이애미 Compositions and methods for treating inflammasome-related diseases or conditions
BR112020027055A2 (en) * 2018-07-17 2021-04-06 Jiangsu Hengrui Medicine Co., Ltd. ANTI-ABETA ANTIBODY, ANTIGEN BINDING FRAGMENT OF THE SAME AND APPLICATION OF THE SAME
CN111217912B (en) * 2018-11-26 2022-11-08 东莞市朋志生物科技有限公司 Antibody against PG II and application thereof
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
IL266433B (en) 2019-05-02 2020-11-30 Sagi Irit Compositions comprising the propeptide of lysyl oxidase and uses thereof
WO2020254670A1 (en) * 2019-06-21 2020-12-24 Università Degli Studi Magna Graecia Catanzaro Monoclonal antibody targeting a unique cancer-associated epitope of cd43
US20220268789A1 (en) * 2019-07-05 2022-08-25 Shimadzu Corporation Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody
EP4028127A1 (en) * 2019-09-10 2022-07-20 AC Immune SA Novel molecules for diagnosis
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
EP4121108A4 (en) * 2020-03-18 2024-04-03 Elanco US Inc. ANTI-IL4 RECEPTOR ANTIBODIES FOR VETERINARY USE
JP2023528797A (en) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド Methods of treating inflammatory diseases by blocking galectin-3
CN112480250B (en) * 2020-12-23 2022-03-15 上海交通大学 Anti-human osteopontin antibody and application thereof
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
EP4399218A4 (en) * 2021-08-30 2025-10-29 Brigham & Womens Hospital Inc METHODS AND MATERIALS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
KR20240131324A (en) * 2021-11-03 2024-08-30 럿거스, 더 스테이트 유니버시티 오브 뉴 저지 Antibody-drug conjugates to the receptor tyrosine kinase EphA5
KR20240125969A (en) * 2021-12-21 2024-08-20 에이치비브이테크, 엘엘씨. Method for removing hepatitis B virus CCCDNA and RCDNA and hepatitis B drug used in the method
WO2023156999A1 (en) 2022-02-17 2023-08-24 Yeda Research And Development Co. Ltd. Propeptide of lysyl oxidase for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493825A (en) 1982-10-05 1985-01-15 Iowa State University Research Foundation Purified and antigenically selective vaccines for domestic animals
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
CA2115900A1 (en) * 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
FR2702049B1 (en) 1993-02-24 1995-03-31 Imra Europe Sa Method and device for determining the risk of water condensation on a surface in contact with a volume of humid air.
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE69841122D1 (en) 1997-03-10 2009-10-15 Coley Pharm Gmbh Use of non-methylated CpG dinucleotide in combination with aluminum as adjuvants
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
IL138608A0 (en) * 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2005011599A2 (en) * 2003-08-01 2005-02-10 Northwestern University Antibodies specific for toxic amyloid beta protein oligomers
EP1660533A4 (en) 2003-09-12 2009-10-21 Univ California SPECIFIC MONOCLONAL ANTIBODIES MADE FROM PROTEINS OF DIFFERENT SEQUENCES FOR HIGHLY MOLECULAR AGGREGATIVE INTERMEDIATE PRODUCTS OF AMYLOIDS
EP1812062B1 (en) * 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US9637549B2 (en) 2009-11-30 2017-05-02 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US10894836B2 (en) 2009-11-30 2021-01-19 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
US8128930B2 (en) 2012-03-06
EP2465872A3 (en) 2012-12-19
BRPI0617480A2 (en) 2017-07-11
CA2584859A1 (en) 2006-05-26
JP5634975B2 (en) 2014-12-03
JP2012097096A (en) 2012-05-24
US20060228349A1 (en) 2006-10-12
US20120171224A1 (en) 2012-07-05
IL182554A0 (en) 2007-09-20
JP2008520553A (en) 2008-06-19
NO20072700L (en) 2007-07-25
BRPI0516962A (en) 2008-09-30
JP2013035843A (en) 2013-02-21
WO2006055178A2 (en) 2006-05-26
EP1812062A2 (en) 2007-08-01
US8889138B2 (en) 2014-11-18
JP2012087139A (en) 2012-05-10
KR20070094890A (en) 2007-09-27
EP2465872A2 (en) 2012-06-20
US7811563B2 (en) 2010-10-12
US7780963B2 (en) 2010-08-24
AU2005306997A1 (en) 2006-05-26
EP1812062B1 (en) 2022-03-09
CA2584859C (en) 2017-11-07
US8383113B2 (en) 2013-02-26
RU2007119382A (en) 2008-11-27
JP5173426B2 (en) 2013-04-03
NZ554725A (en) 2009-10-30
US20080175835A1 (en) 2008-07-24
US20100272714A1 (en) 2010-10-28
IL190502A0 (en) 2008-11-03
EP1812062A4 (en) 2012-12-19
AU2005306997B2 (en) 2012-07-05
US20110159013A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
WO2006055178A3 (en) Anti-addl antibodies and uses thereof
WO2007050359A3 (en) Anti-addl monoclonal antibody and use thereof
WO2012009442A3 (en) Anti-addl monoclonal antibody and uses thereof
WO2006107814A3 (en) Methods for measuring the metabolism of neurally derived biomolecules in vivo
WO2006118959A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
WO2006040153A3 (en) Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2008068024A3 (en) Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2002088307A3 (en) Humanized antibodies
WO2002088306A3 (en) Humanized antibodies
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
WO2003040325A3 (en) Novel proteins and nucleic acids encoding same
Bu et al. Deciphering the multifunctional role of dual leucine zipper kinase (DLK) and its therapeutic potential in disease
WO2003083046A3 (en) Novel proteins and nucleic acids encoding same
WO2005076939A3 (en) Assay and method for diagnosing and treating alzheimer’s disease
WO2003023001A3 (en) Novel proteins and nucleic acids encoding same
WO2003029424A3 (en) Novel proteins and nucleic acids encoding same
WO2003064628A3 (en) Novel proteins and nucleic acids encoding same
WO2003102159A3 (en) Novel proteins and nucleic acids encoding same
WO2007047323A3 (en) Methods to treat alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject
WO2004047854A3 (en) Methods for the treatment of alzheimers disease and compositions therefore
WO2005002573A3 (en) Methods for using modulators of proline-rich tyrosine kinase 2
WO2005072241A3 (en) Inhibition of bright function as a treatment for excessive immunoglobulin production

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580036717.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005306997

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 182554

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 551/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2584859

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004909

Country of ref document: MX

Ref document number: 2007538122

Country of ref document: JP

Ref document number: 554725

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005820737

Country of ref document: EP

Ref document number: 1020077011785

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007119382

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005820737

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11577426

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516962

Country of ref document: BR